| Name | Title | Contact Details |
|---|---|---|
Stephen Lawniczak |
AbbVie Chief Ethics & Compliance Officer | Profile |
Cindy K |
Associate Director, Business Human Resources - Oncology | Profile |
Assil O |
Chief Equity Officer and Vice President People Experience | Profile |
Kari Haley |
HR Systems/HCM ASC Director | Profile |
Kaitlynn Koeppler |
Director, Talent Acquisition | Profile |
Balance Pharmaceuticals is a Pacific Palisades, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chartwell Pharmaceuticals is a Congers, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BONESUPPORT AB is a Scandinavian orthobiologics company that develops and markets CERAMENT®, an innovative range of radiopaque injectable osteoconductive and drug-eluting bioceramic products that have a proven ability to heal defects by remodeling to h...
Our local centers provide infusion care such as Remicade, Ocrevus, and Entyvio and injections like Xolair and Fasenra for patients with ongoing conditions.
Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. Our complex mixture generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While we use a similar analytical and development approach across all of our product candidates, we tailor that approach for each specific product candidate. Our first objective is to apply our core analytical technology to thoroughly characterize the structure of the marketed product. By defining the chemical composition of multiple batches of a marketed product, we are able to develop an equivalence window which captures the inherent variability of the innovator`s manufacturing process. Using this information, we then build an extensive understanding of the structure-process relationship to design and control our manufacturing process to manufacture reproducibly an equivalent version of the marketed product. Where necessary, and as required by the U.S. Food and Drug Administration, or FDA, we will supplement an application with additional supportive structure-activity data (e.g., immunogenicity, pharmacodynamics). Our goal is to obtain FDA approval for and commercialize generic or follow-on versions of complex mixture products, thereby providing high quality, safe and affordable medicines to patients in need.